INSIGHT (R)XT. Indications for Diagnosis, Arrhythmia and Monitoring of Reveal XT
|Atrial Fibrillation Cardiac Arrhythmias|
|Study Design:||Time Perspective: Prospective|
|Official Title:||Indications for Diagnosis, Arrhythmia and Monitoring of Reveal XT.|
- descriptive: clinical indications for Reveal XT [ Time Frame: 2008-2012 ]To describe the patient population implanted with a Reveal XT for arrhythmia diagnosis and monitoring
|Study Start Date:||April 2008|
|Study Completion Date:||April 2013|
|Primary Completion Date:||April 2013 (Final data collection date for primary outcome measure)|
Improving the diagnosis and management of cardiac rhythm disturbances remains a major challenge for physicians. Limitations of current cardiac arrhythmia monitoring using ECG, holters or event recorders are that these methods are non-continuous and/or automatic arrhythmia detection is often impossible. The Medtronic Reveal XT Insertable Cardiac Monitor is a programmable device which continuously monitors the patient's subcutaneous ECG and provides information regarding arrhythmia episodes, long term trending of AF burden, patient's activity and heart rate variability. The Reveal XT records cardiac information in response to patient activation and automatically detected arrhythmias thereby offering advantages over conventional tools for long-term arrhythmia monitoring with regard to compliance and recording time.
The clinical applications for Reveal XT are varied. Diagnostic, arrhythmia monitoring and arrhythmia management functions can be discriminated.
This study is a prospective, observational, multicenter international post-market study. The results of this study will describe the different patient groups for which the Reveal XT is being used for the diagnosis and monitoring of various cardiac arrhythmias. This study will also collect data regarding the clinical consequences of using the Reveal XT and the influence of Reveal XT data on clinical care pathways. The physician as well as the patient's satisfaction with the device will be evaluated. The study will be conducted in 60-100 centers primarily in Europe. It is expected that 800-1000 patients will be enrolled.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00680550
Show 56 Study Locations
|Study Chair:||Guido Rieger, MD||Medtronic Bakken Research Center BV|